ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IBRX · as of Mar 31, 2025
Ownership Breakdown
222
Institutional Holders
▲ 10 vs Q4
$249.76M
Total Inst. Value
▲ $37.99M vs Q4
1.05B
Shares Outstanding
freeFloat 10.87%
81.31M
13F Shares Held
▼ 1.37M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IBRX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 20.34M | 2.38% | 2.38% | $61.24B | May 9, 2025 | ▲ 3.02M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 13.29M | 1.56% | 1.56% | $40.00B | May 2, 2025 | ▼ 294.7K |
STATE STREET CORP biological products, (no diagnostic substances) | 7.58M | 88.89% | 88.89% | $22.83B | May 15, 2025 | ▼ 2.20M |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.29M | 50.28% | 50.28% | $12.91B | May 13, 2025 | ▲ 448.5K |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 3.45M | 40.38% | 40.38% | $10.37B | May 15, 2025 | ▲ 2.7K |
CITIGROUP INC biological products, (no diagnostic substances) | 2.71M | 31.82% | 31.82% | $8.17B | May 12, 2025 | ▲ 2.33M |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.33M | 27.35% | 27.35% | $7.02B | May 15, 2025 | ▼ 480.9K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.90M | 22.21% | 22.21% | $5.70B | May 15, 2025 | ▼ 2.11M |
OCTAGON CAPITAL ADVISORS LP biological products, (no diagnostic substances) | 1.72M | 20.16% | 20.16% | $10.37B | May 15, 2025 | NEW |
UBS GROUP AG biological products, (no diagnostic substances) | 1.44M | 16.86% | 16.86% | $4.33B | May 13, 2025 | ▼ 149.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+10.69M shares3
New Positions
first time holders13
Decreased
−5.98M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.71M
+10.69M / −5.98M
Net new holders
+17
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IBRX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Simon Barry J. director | Jun 4, 2026 | Sale | 23,033 | $7.18 | $165.3K | 2.83M | Form 4 ↗ |
SOON-SHIONG PATRICK See remarks | Mar 31, 2026 | C-Conversion | 4,606,596 | $5.43 | $25.00M | 251.02M | Form 4 ↗ |
SOON-SHIONG PATRICK See remarks | Mar 31, 2026 | C-Conversion | 0 | $5.43 | $0 | 0 | Form 4 ↗ |
Simon Barry J. director | Feb 24, 2026 | Sale | 75,000 | $12.01 | $900.8K | 2.85M | Form 4 ↗ |
Selecky Christobel director | Feb 23, 2026 | Sale | 25,000 | $10.00 | $250.0K | 0 | Form 4 ↗ |
Sachs David C. Chief Financial Officer | Feb 22, 2026 | Tax Withhold | 20,682 | $8.70 | $179.9K | 300.1K | Form 4 ↗ |
SOON-SHIONG PATRICK See remarks | Feb 22, 2026 | Tax Withhold | 58,170 | $8.70 | $506.1K | 29.76M | Form 4 ↗ |
LAUER REGAN J Chief Accounting Officer | Feb 22, 2026 | Tax Withhold | 1,673 | $8.70 | $14.6K | 115.9K | Form 4 ↗ |
Adcock Richard CEO & President | Feb 22, 2026 | Tax Withhold | 77,560 | $8.70 | $674.8K | 560.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ImmunityBio, Inc. (IBRX) is primarily owned by institutional investors, who hold approximately 7.8% of total shares outstanding. Company insiders own approximately 89.13%, while retail and public investors account for the remaining 3.11%.
The largest institutional shareholder of ImmunityBio, Inc. is VANGUARD GROUP INC, holding approximately 20.34 million shares — equal to 2.38% of outstanding shares — as of March 31, 2025.
A total of 222 institutional investors currently hold IBRX stock, with a combined institutional value of approximately $249,760,280 as of the most recent 13F filing period.
Frequently asked questions
IBRX ownershipImmunityBio, Inc. (IBRX) is primarily owned by institutional investors, who hold approximately 7.8% of shares. The largest shareholder is VANGUARD GROUP INC with a 2.38% stake. Company insiders hold 89.13%. Data sourced from SEC Form 13F as of March 31, 2025.